Third regulatory submission for Alzheimer's hopeful

10 December 2020

Following regulatory bids in Europe and Japan, aducanumab developers Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have now formally submitted for approval in Japan.

The treatment has shown promise in treating Alzheimer’s, with tests showing it can slow clinical decline in people with mild cognitive impairment and mild dementia.

The candidate is under consideration in the USA with Priority Review, with a decision expected by March 7, 2021. The European regulator started working on its review around a month ago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK